ArticleBiotechnology and bioengineering2015
Engineering the oxygen sensing regulation results in an enhanced recombinant human hemoglobin production by Saccharomyces cerevisiae.
Article in Biotechnology and bioengineering, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 31 citations in OpenAlex.
- Valorization of Miscanthus × giganteus hydrolysates into heme-enriched yeast biomass and extract using xylose-fermenting Saccharomyces cerevisiae.Bioresources and bioprocessing · 2026Article
- Metabolic engineering of yeast to efficiently synthesize heme and hemoproteins: recent advance and prospects.FEMS yeast research · 2025Review
- High-level expression of leghemoglobin inFrontiers in bioengineering and biotechnology · 2023Article
- Genome-scale modeling drives 70-fold improvement of intracellular heme production inProceedings of the National Academy of Sciences of the United States of America · 2022Article
- Yeasts as Biopharmaceutical Production Platforms.Frontiers in fungal biology · 2021Article
- Intrinsically Magnetic Cells: A Review on Their Natural Occurrence and Synthetic Generation.Frontiers in bioengineering and biotechnology · 2020Review
- How Synthetic Biology and Metabolic Engineering Can Boost the Generation of Artificial Blood Using Microbial Production Hosts.Frontiers in bioengineering and biotechnology · 2018Review
- The impact of respiration and oxidative stress response on recombinant α-amylase production byMetabolic engineering communications · 2016Article
- Heme metabolism in stress regulation and protein production: From Cinderella to a key player.Bioengineered · 2016Article
- Optimizing cofactor availability for the production of recombinant heme peroxidase in Pichia pastoris.Microbial cell factories · 2015Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Efficient production of appropriate oxygen carriers for transfusions (blood substitutes or artificial blood) has been pursued for many decades, and to date several strategies have been used, from synthetic polymers to cell-free hemoglobin carriers. The recent advances in the field of metabolic engineering also allowed the generation of different genetically modified organisms for the production of recombinant human hemoglobin. Several studies have showed very promising results using the bacterium Escherichia coli as a production platform, reporting hemoglobin titers above 5% of the total cell protein content. However, there are still certain limitations regarding the protein stability and functionality of the recombinant hemoglobin produced in bacterial systems. In order to overcome these limitations, yeast systems have been proposed as the eukaryal alternative. We recently reported the generation of a set of plasmids to produce functional human hemoglobin in Saccharomyces cerevisiae, with final titers of active hemoglobin exceeding 4% of the total cell protein. In this study, we propose a strategy for further engineering S. cerevisiae by altering the oxygen sensing pathway by deleting the transcription factor HAP1, which resulted in an increase of the final recombinant active hemoglobin titer exceeding 7% of the total cellular protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.